KRAS-G12D inhibitor HRS-4642 plus chemotherapy in advanced KRASG12D-mutant pancreatic cancer: a phase 1b/2 trial
- DOI
- 10.1038/s41591-026-04538-9
- Published
- 2026-07-09
- Container
- Nature Medicine
- Publisher
- Springer Science and Business Media LLC
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1038/s41591-026-04538-9,
title = {KRAS-G12D inhibitor HRS-4642 plus chemotherapy in advanced KRASG12D-mutant pancreatic cancer: a phase 1b/2 trial},
author = {Jiujie Cui and Kuirong Jiang and Wei Li and Shuqin Ni and Hong Zong and Juan Du and Yifu He and Zhonghua Liu and Guoqiang Kong and Yanqiao Zhang and Xiaotong Li and Hongxia Han and Fen Yao and Yongwu Chen and Ming Zhou and Liwei Wang},
year = {2026},
journal = {Nature Medicine},
doi = {10.1038/s41591-026-04538-9},
url = {https://doi.org/10.1038/s41591-026-04538-9}
}RIS
TY - JOUR TI - KRAS-G12D inhibitor HRS-4642 plus chemotherapy in advanced KRASG12D-mutant pancreatic cancer: a phase 1b/2 trial AU - Jiujie Cui AU - Kuirong Jiang AU - Wei Li AU - Shuqin Ni AU - Hong Zong AU - Juan Du AU - Yifu He AU - Zhonghua Liu AU - Guoqiang Kong AU - Yanqiao Zhang AU - Xiaotong Li AU - Hongxia Han AU - Fen Yao AU - Yongwu Chen AU - Ming Zhou AU - Liwei Wang PY - 2026 JO - Nature Medicine DO - 10.1038/s41591-026-04538-9 UR - https://doi.org/10.1038/s41591-026-04538-9 ER -
APA
Cui, J., Jiang, K., Li, W., Ni, S., Zong, H., Du, J., He, Y., Liu, Z., Kong, G., Zhang, Y., Li, X., Han, H., Yao, F., Chen, Y., Zhou, M., & Wang, L. (2026). KRAS-G12D inhibitor HRS-4642 plus chemotherapy in advanced KRASG12D-mutant pancreatic cancer: a phase 1b/2 trial. Nature Medicine. https://doi.org/10.1038/s41591-026-04538-9
Source records
- crossref · retrieved 2026-09-27T01:13:37.604Z